CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-14). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2556 · Search date 2026-08-14 · Methodology v0.7

Individualised nutritional support,
does it really help with Reduction in the 30-day composite of death, ICU admission, non-elective readmission, major complications, or functional decline?

30-Second Summary
B
Evidence Grade B · 72 · Safety caution
Individualised nutrition reduced 30-day clinical events in one publicly funded randomized trial of at-risk medical inpatients.
Enteral or parenteral feeding and rapid nutritional escalation require clinical monitoring for aspiration, fluid or electrolyte disturbances, and refeeding syndrome.
What the
research shows
The grade is B. EFFORT randomized 2,088 patients and analyzed 1,015 versus 1,013 after consent withdrawals. The 30-day composite occurred in 232/1,015 (22.9%) versus 272/1,013 (26.9%), adjusted OR 0.79 (95% CI 0.64 to 0.97). This is a 4.0-point absolute reduction, about NNT 25, but it remains one confirmatory trial with 60 post-randomization exclusions, giving B with 72 points.
What the
ads claim
The tested intervention was screening plus dietitian-set targets and stepped oral, enteral, or parenteral support, not one drink or a uniform product for every inpatient.
*

Useful facts when choosing a product

  • Support began within 48 hours and followed individualized calorie and protein goals.
  • Calorie goals were reached by 800/1,015 and protein goals by 770/1,015.
  • No duplicate intervention-endpoint combination was identified in the existing list.
Gap Measurement · Verdict 2556 · B 72
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

This open pragmatic trial at eight Swiss hospitals randomized 1,050 versus 1,038 patients. After 35 versus 25 withdrew consent, primary analysis included 1,015 versus 1,013. Allocation used centralized web randomization, and the registered and published primary composite matched. Blinding patients and dietitians was infeasible, but outcomes were event based. Funding came from the Swiss National Science Foundation and the Research Council of Kantonsspital Aarau.

02

Why this is classified as B (72)

A publicly funded multicenter trial reduced patient-important 30-day events, but there is no independent replication and 60 randomized patients were excluded after consent withdrawal, giving B with 72 points.

Counterpoint. B applies to a managed nutrition program for screened at-risk inpatients, not to every nutrition product.

Rejudgment record. Cross-check applied — We cross-checked the EFFORT paper and registry for the primary outcome, analysis denominators, event counts, centralized randomization, and public funding.

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced 30-day adverse clinical outcomesBRates were 22.9% versus 26.9%, adjusted OR 0.79.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Eight-hospital open-label pragmatic randomized trial1,013Swiss National Science Foundation and Research Council of Kantonsspital Aarau30-day adverse clinical outcome composite232/1,015 (22.9%) versus 272/1,013 (26.9%), adjusted OR 0.79 (95% CI 0.64 to 0.97), P=0.023Pivotal publicly funded hard-outcome RCT
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-14).

Schuetz P, Fehr R, Baechli V, Geiser M, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet. 2019;393:2312-2321. PMID: 31030981. DOI: 10.1016/S0140-6736(18)32776-4.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-14 · Corrections: none

Cite this verdict

Individualised nutritional support x fewer 30-day clinical events in at-risk medical inpatients Evidence Grade B card
[Chamgap] Individualised nutritional support x fewer 30-day clinical events in at-risk medical inpatients — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/individualised-nutritional-support-medical-inpatients-30-day-outcomes/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.